

## Patient Benefit by Scientific Collaboration

Greg Rullo
CMC Regulatory Affairs
AstraZeneca




### Scientific collaboration to advance quality medicines to patients


2 year path from September of 2021 to M-CERSI workshop



Case study	Company	Case study
1	Amgen	Amgen-Drug-x
2	Astrazeneca	Lesinurad
3	Astrazeneca	Acalabrutinib
4	EMD (Merck KGaA)	EMD-Drug-A
5	Janssen	Janssen-Drug-A
6	Janssen	Janssen-Drug-B
7	Merck & Co (MSD)	Etoricoxib
8	Novartis	Ribociclib
9	Pfizer	Fluconazole
10	Roche	Roche-Drug-A
11	Sanofi	Sanofi-Drug-A
12	Vertex	Vertex-Drug-A



#### Workshop Scientific Collaboration: Industry-Regulators- Academics



#### Choices, Chances and Change

#### Make a Choice to take a Chance for us to see Change

- Workshops: European based, Brazil, Canada and Japan?
- Publications:
  - 3 day workshop 3 publications + 1 summary publication
  - White paper best practice on for PBBM reports
- ICH Guideline:
  - ICH M15 General Principles for Model Informed Drug Development
    - Provides a framework for model development and validation
  - ICH M12 Drug Interaction Studies (M12 applications of PBPK)
  - ICH Mx Physiological Based Biopharmaceutic Models



## Acknowledgements





















Claire Mackie Tyco Heimbach Christer Tannergren

Sumit Arora Anamitro Banerjee Mitra Amitava

Xavier Pepin Sandra Suarez-Sharp Jamei Masoud

Sponsors

AstraZeneca Takeda Roche

Janssen Tycho Heimbach Certara

All Moderators, Speakers, Scribes and all Workshop Participants



# Thank You

